Safety and Immunogenicity of a Live Recombinant Canarypox Virus Expressing HIV Type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) Followed by a p24E-V3 MN Synthetic Peptide (CLTB-36) Administered in Healthy Volunteers at Low Risk for HIV Infection

A live recombinant canarypox vector expressing HIV-1 gpl20 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) alone or boosted by a p24E-V3 MN synthetic peptide (CLTB-36) was tested in healthy volunteers at low risk for HIV infection for their safety and immunogenicity. Both antigens were well tolerated. ALVAC-HIV (vCP205) induced low levels of neutralizing antibodies against HIV-1 MN in 33% of the volunteers. None of them had detectable neutralizing...